SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (251)11/26/2002 9:20:27 AM
From: scaram(o)uche  Read Replies (1) of 469
 
listening to replay of webcast now..... first Q in Q&A addressed pricing. Companies didn't answer.

I figure, given Genzyme pricing, that two patients should be about break even.

Switch therapy and simultaneous therapy with cerezyme will be the subject of additional trials.

Guessed that there may be "a few thousand" patients, but they won't know until patients are gathered together, now that there is an alternative. Label is not restricted to mild disease.

interim data from NYU trial will be included in the NDA resubmission.

OGT 923.... right of first refusal through completion of phase I!!!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News